Skip to main content

Table 4 The nine principal components in scaled phenotypic space.

From: A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes

Principal Component 1 2 3 4 5 6 7 8 9
Ritonavir 0.39 0.35 0.60 -0.16 0.30 -0.37 -0.32 -0.05 -0.07
Nelfinavir 0.36 0.33 0.22 -0.05 -0.10 0.31 0.75 -0.11 0.17
Atazanavir 0.39 0.12 -0.10 0.23 0.01 0.72 -0.49 -0.12 -0.04
Amprenavir 0.36 -0.29 -0.17 -0.49 0.29 0.13 0.07 0.63 -0.12
Indinavir 0.33 0.04 -0.14 -0.02 -0.62 -0.23 0.02 -0.02 -0.65
Lopinavir 0.31 -0.12 -0.18 -0.33 -0.43 -0.19 -0.21 -0.15 0.67
Saquinavir 0.38 0.15 -0.48 0.58 0.29 -0.38 0.11 0.14 0.14
Tipranavir 0.23 -0.71 0.48 0.43 -0.12 -0.02 0.07 0.07 0.07
Darunavir 0.19 -0.37 -0.21 -0.23 0.39 -0.04 0.12 -0.72 -0.21
Percent Variance (%) 83.7 6.0 3.1 2.7 1.6 1.0 1.0 0.6 0.3
  1. The first two principal components together capture approximately 90% of the variance in the data and represent development of high resistance toward all drugs and development of high resistance to NFV and RTV with increasing resistance toward ATV, SQV and IDV, respectively.